Image by Solera
March 22, 2018 | By Solera

Cimzia Label Update Provides New Information For Women Of Childbearing Age

The FDA approved a label update of UCB’s Cimzia, or certolizumab pegol, to include new data showing a negligible to low risk for drug transfer through placenta and a minimal risk for transfer through breast milk among pregnant women. The drug is currently approved as a treatment for adult patients with active psoriatic arthritis, moderate to severe active rheumatoid arthritis and active ankylosing spondylitis, as well as to ease the symptoms of Crohn’s disease and maintain clinical response in adult patients with moderate to severe active disease who do not respond adequately to conventional therapy.

Click Here to view the original article at MPR (login required)


A smaller focus to make a much larger impact. Our goal is to deliver on every promise we make

Our Mission

Learn More